Leerink initiated coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and a 12-month price target of $21. The stock closed at $13.21 on Feb. 17.Read More
Titan Pharmaceuticals (NASDAQ:TTNP), in a move to boost its product development and commercialization experience in the U.S., Europe and Asia, named Scott Smith and Dr. Rajinder Kumar to its board.Read More
Mackie Research launched coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a “speculative buy” recommendation and a 12-month target price of $8. The stock closed at $3.03 on Monday.
Aurinia is developing voclosporin as a first-line treatment for lupus nephritis (LN) and advancing the drug candidate into Phase 3 trials.Read More
Avivagen (TSX-V:VIV) has made the first industrial-scale sale of its OxC-beta livestock to UNAHCO in the Philippines.
The sale is for 150 kilograms of OxC-beta livestock 10% premix at pricing in line with Avivagen's target. The order will supplement approximately 7.5 million kilograms of UNAHCO-branded commercial feed, an amount sufficient for about three million broiler chickens or 350,000 piglets.Read More
Avivagen (TSX-V:VIV) and UNAHCO have registered OxC-beta Livestock as an imported livestock feed additive, authorizing its use in all species in the Philippines.
UNAHCO is a feed and veterinary unit of Unilab, the largest pharmaceutical company in the Philippines. UNAHCO provides a broad range of animal healthcare and nutrition products and programs to meet the requirements of both large commercial and smaller individual farmers in the Philippines as well as abroad.Read More